Allarity Therapeutics
Boston
About Allarity Therapeutics
Allarity Therapeutics is a biopharmaceutical company that develops oncology products and drugs for the personalized treatment of cancer. The company utilizes drug response predictor technology to refine patient selection and improve clinical outcomes. Its product pipeline includes Dovitinib, a pan-tyrosine kinase inhibitor for renal cell carcinoma (RCC), Stenoparib (2X-121), a dual PARP inhibitor, and Tankyrase Inhibitor for ovarian cancer; IXEMPRA (Ixabepilone), a microtubulin inhibitor for metastatic breast cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Total funding: $38.5M
- Funding stage: IPO
- Last round: Post-IPO Debt (Mar 2026)
- Ticker: nasdaq:ALLR
- Website: allarity.com
- Phone: 401-426-4664
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/allarity-therapeutics-80465 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.